Cornucopian Capital

We are privileged to be included in the investor group led by Madrona supporting the launch of Archon Biosciences, a platform for accelerating the delivery of antibody-based therapeutics. Led by co-founders James Lazarovits and George Ueda, two world class researchers from Nobel prize winning David Baker’s Lab at the Institute for Protein Design, University of Washington (IPD), Archon is developing an entirely new class of biologics by creating Antibody Cages (AbCs), AI-generated protein structures that can improve the delivery of antibody therapies targeting specific areas of the body. Our venture partners, Matt Dittrich and Robby Divine (a brilliant early scientist in the field of AbCs who’s PhD served as foundational research for Archon), and Advisors Justin Siegel, Erich Veitenheimer, and Ingrid Pultz all made this investment possible. We look forward to a long-term relationship with Jamie, George, and the entire Archon family!

Understanding how our body’s clock regulates key physiological processes can unlock more precise and personalized approaches to improving our healthspan. This IIFH event was an amazing opportunity to learn more about the emerging technologies and science focused on Circadian Health! Here are some of our key takeaways: ·      Daylight exposure is a strong predictor of sleep onset, with natural light during the day potentially more effective than limiting evening light for improving sleep. Thank you, Horacio Hacho De La Iglesia, for sharing your research and discussing new lighting technologies designed to improve circadian health. ·      Around 40% of adolescents struggle with irregular sleep patterns, which are linked to poorer academic performance, attention deficits, and mental health challenges. Thank you, Michael Grandner, for highlighting the potential of sleep telehealth platforms in improving circadian health, with promising implications for implementation in other at-risk populations, including children. ·      Over 80% of FDA-approved drug targets follow circadian patterns in gene expression, presenting opportunities to optimize treatment timing for better efficacy. Thank you, John Hogenesch and @Ron Anafi, for sharing your work on developing new technologies to accurately measure and identify new circadian biomarkers, offering exciting potential for clinical applications. ·      Strong biological rhythms are a marker of health and longevity and can be strengthened by maintaining healthy sleeping and eating patterns. Thank you, Satchin Panda, Emily Manoogian, Marie-Pierre St-Onge, Joe Bass, and Joanna Chiu, for sharing insights on the importance of meal tim

Another fascinating Medicine 3.0 Symposium yesterday, when scientists, innovators, entrepreneurs, and investors came together to discuss GLP-1 agonists and their impact on metabolic health and muscle performance. Here are some key takeaways: • Next gen therapeutics combining peptides with greater efficacy look promising for those that need them. Thank you, Shirly Pinto PhD for sharing your insights on the pharma pipeline, including challenges and opportunities ahead. • Too many people are struggling to maintain weight loss if/when they go off Ozempic et al. Given that rapid weight loss is often accompanied by 40% muscle mass loss, regaining the weight – mostly body fat – results in losing functionality. Thank you, Keith Baar, for sharing your research on skeletal muscle health and the risks associated with rapid weight loss. • Ultimately, with 30M people projected to be on GLP-1 drugs by 2030, consumer behaviors will change and drive new product solutions. Thank you, Joshua C Anthony, PhD, MBA, for describing some of the innovation opportunities that food and nutrition companies should consider to meet new consumer demands. • Finally, thank you Richard Johnson, for a fascinating presentation on the biology of obesity, GLP-1 pathways and mechanisms of action, and alternative solutions for activating GLP-1 receptors (e.g. Allulose), that should be explored in the future. • Understanding the complexities of GLP-1 agonists from different perspectives – from pharma, academia, and food system stakeholders – is essential for appreciating the significance of the ‘Ozempic frenzy’ we’re witnessing today. Jessica Muse, you did a remarkable job moderating this discussion on short notice!

Cornucopian Capital is looking forward to another NYC Medicine 3.0 Symposium, focused on GLP-1 agonists and the impacts on weight loss and muscle health. If you are in the NYC area, and are interested in joining, please use the registration link below. Space is limited, so early registration is encouraged. https://lnkd.in/e3yEbhDC Thank you to Cooley LLP for hosting this event, and to our esteemed panelists, Richard Johnson, Elina Onitskansky, Keith Baar, Joshua C Anthony, PhD, MBA, and Shirly Pinto PhD, for joining us for this valuable discussion!

Cornucopian Capital is looking forward to another NYC Medicine 3.0 Symposium, focused on GLP-1 agonists and the impacts on weight loss and muscle health. If you are in the NYC area, and are interested in joining, please use the registration link below. Space is limited, so early registration is encouraged. https://lnkd.in/e3yEbhDC Thank you to Cooley LLP for hosting this event, and to our esteemed panelists, Richard Johnson, Elina Onitskansky, Keith Baar, Joshua C Anthony, PhD, MBA, and Shirly Pinto PhD, for joining us for this valuable discussion!

Thank you Dr. Nicole Avena, Gil Blander, Arshad K Rahim, MD, MBA, FACP, Justin Siegel, and Robert Lustig for yesterday’s engaging Symposium in NYC on how we can address sugar addiction in both food systems and healthcare. And a special thank you to Patrick McCurry and the McDermott team for hosting us! Nicole’s new book, "Sugarless", distills her 20+ years of pioneering research on how our sugar intake affects our brains and metabolic processes - AND provides practical solutions for each of us to reduce everyday sugar consumption to improve our healthspan. Check it out!

We are looking forward to sponsoring this event! If you would like to join us for an world-class discussion on how we can address the negative effects of sugar consumption, we would welcome you to join us! Spaces are limited, and registration is required using the following link below:

Is your VO2max in a healthy range? VO2max has been a popular metric among endurance athletes trying to improve their performance, but growing research shows that everyone should monitor their VO2max for longevity. Higher levels of VO2max are associated with improved heart health, better glucose control, lower inflammation levels, stronger athletic performance, and increased healthspan. Although VO2max naturally declines with age, it's highly modifiable through lifestyle changes. Knowing your levels means you can take action towards a longer healthier life. Check out our new article to learn what a "good" VO2max level is for you, how to improve it, and why it's critical for healthspan: https://hubs.li/Q02hj0XB0

🥕🧬 Check out our latest blog post on the burgeoning #market for #PersonalizedNutrition in the quest for #longevity! Meet Bobby Biohacker 📱, Willow Wellness 🏋🏿♀️, and Mary Medical 🍎, the archetype consumers of this market. Learn about the different strategies companies are using in this space 📈. #Nutrition #LongevityLifestyle #PrecisionNutrition #HealthAndWellness #NutritionTrends